Unfortunately, all NA-NSAIDS, including selective COX-2 inhibitors, are associated with significant side effects, which hinder their use as CRC chemopreventive agents apart from FAP patients due to their high risk of developing CRC [93,103]. The gene discussed is PTGS2; the disease is Familial adenomatous polyposis.